These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. An anthraquinone derivative, emodin sensitizes hepatocellular carcinoma cells to TRAIL induced apoptosis through the induction of death receptors and downregulation of cell survival proteins. Subramaniam A, Loo SY, Rajendran P, Manu KA, Perumal E, Li F, Shanmugam MK, Siveen KS, Park JI, Ahn KS, Hui KM, Kumar AP, Sethi G. Apoptosis; 2013 Oct; 18(10):1175-87. PubMed ID: 23700228 [Abstract] [Full Text] [Related]
24. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis. Yamanaka Y, Shiraki K, Inoue T, Miyashita K, Fuke H, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K, Nakano T. Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154 [Abstract] [Full Text] [Related]
25. Resistance to Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-infected T-cell lines. Matsuda T, Almasan A, Tomita M, Uchihara JN, Masuda M, Ohshiro K, Takasu N, Yagita H, Ohta T, Mori N. J Virol; 2005 Feb; 79(3):1367-78. PubMed ID: 15650163 [Abstract] [Full Text] [Related]
26. Sensitization of TRAIL-induced apoptosis in human hepatocellular carcinoma HepG2 cells by phytochemicals. Abou El Naga RN, Azab SS, El-Demerdash E, Shaarawy S, El-Merzabani M, Ammar el-SM. Life Sci; 2013 Mar 21; 92(10):555-61. PubMed ID: 23352978 [Abstract] [Full Text] [Related]
30. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K, Walczak H. Hepatology; 2005 Sep 21; 42(3):588-97. PubMed ID: 16037944 [Abstract] [Full Text] [Related]
31. Regulation of TNF-related apoptosis-inducing ligand-mediated death-signal pathway in human beta cells by Fas-associated death domain and nuclear factor kappaB. Ou D, Wang X, Metzger DL, Robbins M, Huang J, Jobin C, Chantler JK, James RF, Pozzilli P, Tingle AJ. Hum Immunol; 2005 Jul 21; 66(7):799-809. PubMed ID: 16112027 [Abstract] [Full Text] [Related]
32. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Ng CP, Zisman A, Bonavida B. Prostate; 2002 Dec 01; 53(4):286-99. PubMed ID: 12430140 [Abstract] [Full Text] [Related]
33. The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells. Szliszka E, Helewski KJ, Mizgala E, Krol W. Int J Oncol; 2011 Oct 01; 39(4):771-9. PubMed ID: 21743964 [Abstract] [Full Text] [Related]
34. Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis. Iacomino G, Medici MC, Russo GL. Anticancer Res; 2008 Oct 01; 28(2A):855-64. PubMed ID: 18507029 [Abstract] [Full Text] [Related]
35. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5. Choi SY, Kim MJ, Chung HY, Lee SJ, Jang YJ. Oncol Rep; 2007 Jan 01; 17(1):175-84. PubMed ID: 17143496 [Abstract] [Full Text] [Related]
36. Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation. Chen JJ, Chou CW, Chang YF, Chen CC. J Immunol; 2008 Jun 15; 180(12):8030-9. PubMed ID: 18523266 [Abstract] [Full Text] [Related]
37. Transforming growth factor-alpha inhibits the intrinsic pathway of c-Myc-induced apoptosis through activation of nuclear factor-kappaB in murine hepatocellular carcinomas. Cavin LG, Wang F, Factor VM, Kaur S, Venkatraman M, Thorgeirsson SS, Arsura M. Mol Cancer Res; 2005 Jul 15; 3(7):403-12. PubMed ID: 16046551 [Abstract] [Full Text] [Related]
38. NF-kappaB inhibition reveals differential mechanisms of TNF versus TRAIL-induced apoptosis upstream or at the level of caspase-8 activation independent of cIAP2. Diessenbacher P, Hupe M, Sprick MR, Kerstan A, Geserick P, Haas TL, Wachter T, Neumann M, Walczak H, Silke J, Leverkus M. J Invest Dermatol; 2008 May 15; 128(5):1134-47. PubMed ID: 17989734 [Abstract] [Full Text] [Related]
39. Galectin-1 Modulates the Survival and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Sensitivity in Human Hepatocellular Carcinoma Cells. Li J, Sun RR, Yu ZJ, Liang H, Shen S, Kan Q. Cancer Biother Radiopharm; 2015 Oct 15; 30(8):336-41. PubMed ID: 26348206 [Abstract] [Full Text] [Related]
40. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-κB. Ma Y, Wang J, Liu L, Zhu H, Chen X, Pan S, Sun X, Jiang H. Cancer Lett; 2011 Feb 01; 301(1):75-84. PubMed ID: 21078540 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]